Methylphenidate. An update on extended-release formulations
Neurosciences. 2007; 12 (1): 3-7
en Inglés
| IMEMR
| ID: emr-84586
ABSTRACT
Methylphenidate remains the mainstay of pharmacological management in attention deficit hyperactivity disorder [ADHD]. Despite having been available for over half a century, methylphenidate's original formulation has been modified with the main purpose of extending its duration of action. This article will present a brief review of how these new formulations vary and how these should be selected, considering the evidence available on their effectiveness and on the individual needs of the patient
Buscar en Google
Índice:
IMEMR (Mediterraneo Oriental)
Asunto principal:
Trastorno por Déficit de Atención con Hiperactividad
/
Metilfenidato
Idioma:
Inglés
Revista:
Neurosciences
Año:
2007
Similares
MEDLINE
...
LILACS
LIS